依替巴肽用于急性冠状动脉综合征及经皮冠状动脉介入治疗患者的药物经济学系统评价

摘要/Abstract

摘要： 的:对依替巴肽用于急性冠状动脉综合征（ACS）及经皮冠状动脉介入治疗（PCI）患者的药物经济学特性进行系统评价，以期为临床合理用药提供循证参考，为医药卫生、医保决策提供证据支持。方法:系统检索PubMed、The Cochrane Library、中国知网（CNKI）、万方和维普等数据库，根据纳入与排除标准筛选相关文献，并使用卫生经济学评价报告标准共识（CHEERS）量表进行质量评价，对研究结果进行系统性评价分析，检索时间截至2020年12月31日。结果:共纳入8篇文献，7篇来自国外，1篇来自中国；干预措施6篇是依替巴肽与安慰剂对比，1篇是依替巴肽/替罗非班与阿昔单抗对比，剩余1篇是依替巴肽与替罗非班对比；CHEERS评分结果显示8篇文献质量良好。从评估结果来看，在当时设定的阈值下，ACS或PCI患者应用依替巴肽较标准治疗、阿昔单抗或替罗非班可能更具有经济性。结论:在保证安全性和有效性的前提下，依替巴肽用于急性冠状动脉综合征及经皮冠状动脉介入治疗的患者，具有良好的经济学优势。

关键词: font-size:medium, ">依替巴肽；急性冠状动脉综合征；经皮冠状动脉介入治疗；药物经济学；系统评价

Abstract: Objective: To systematically review the pharmacoeconomics characteristics of eptifibatide in patients with acute coronary syndrome(ACS) and percutaneous coronary intervention(PCI), in order to provide evidence-based reference for clinical rational drug use, and provide evidence to support health and medical insurance decision-making. Methods: PubMed, The Cochrane Library, CNKI, Wanfang and VIP databases were systematically searched. Literatures were selected according to inclusion and exclusion criteria, and the CHEERS scale was used for quality evaluation. The search date ended to December 31st, 2020. Results: A total of 8 articles were included, 7 from abroad and 1 from China. The intervening measures in 6 articles were eptifibatide versus placebo, one was eptifibatide/tirofiban versus abciximab, and the remaining one was eptifibatide versus tirofiban. The results of CHEERS grading showed that all the 8 literatures were of good quality.From the evaluation， it appears that eptifibatide may be more economical than standard therapy, abciximab, or tirofiban for patients with ACS or PCI at the threshold set at that time. Conclusion: On the premise of ensuring safety and effectiveness, etibatepin has economic advantages for patients with ACS and PCI.

Key words: Eptifibatide, ACS, PCI, Pharmacoeconomics, Systematic review

中图分类号:

樊清清, 马林楠, 段石顽, 王颖丽, 李维, 吴宁莉. 依替巴肽用于急性冠状动脉综合征及经皮冠状动脉介入治疗患者的药物经济学系统评价[J]. 中国医药导刊, 2021, 23(12): 956-960.

FAN Qingqing, MA Linnan, DUAN Shiwan, WANG Yingli, LI Wei, WU Ningli. Pharmacoeconomic Systematic Review of Eptifibatide in Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2021, 23(12): 956-960.

参考文献

[1]葛均波,徐永健,王辰.内科学［M].第9版.北京：人民卫生出版社，2018：233.
     [2]刘晓丽,彭萍安,程宇婧.血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂在冠状动脉粥样硬化性心脏病治疗的中国专家共识(2016)[J].心肺血管病杂志,2016,35(12):923-932.
     [3]Marco V, Giuseppe BZ, Matteo T, et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials[J]. European Heart Journal, 2010, 31(1): 35-49.
     [4]Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention[J]. Lancet, 1997, 349(9063):1422-1428.
     [5]Novel dosing regimen of eptifibatide in planned coronary stent implantation(ESPRIT): a randomised, placebo-controlled trial[J]. Lancet, 2000, 356(9247) : 2037-2044.
     [6]张新超,于学忠, 陈凤英,等. 急性冠脉综合征急诊快速诊治指南(2019)[J]. 临床急诊杂志, 2019,(4):10.
     [7]Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards(CHEERS) statement[J]. BMC Medicine, 2013, 11:80.
     [8]Brown R, Armstrong P. Platelet Glycoprotein Ⅱb/Ⅲa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis[J]. Can J Cardiol, 2003,19(2):161-166.
     [9]Brown RE, Henderson RA, Koster D, et al. Cost effectiveness of eptifibatide in acute coronary syndromes: an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet Ⅱb/Ⅱa in unstable Angina: Receptor Suppression Using Integrilin Therapy[J]. European Heart Journal, 2002(1):50-58.
     [10]Dewilde S, Brüggenjürgen B, Nienaber C, et al. Cost-effectiveness of adjunctive eptifibatide in patients undergoing coronary stenting in Germany[J]. Eur J Health Econ, 2012,13(4):381-391.
     [11]Mark DB, Harrington RA, Lincoff AM, et al. Cost-effectiveness of platelet glycoprotein Ⅱb/Ⅲa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes[J]. Circulation, 2000,101(4):366-371.
     [12]Szucs TD, Schwenkglenks M, Berger K, et al. Costs and cost-effectiveness of Eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study[J]. Z Kardiol, 2003,92(3):236-244.
     [13]Dewilde S, Opolski G, Brown R. Cost-effectiveness of eptifibatide in NSTEMI patients in Poland[J]. Value in Health, 2005,8(6):A111-A112.
     [14]Glaser R, Glick HA, Herrmann HC, et al. The role of risk stratification in the decision to provide upstream versus selective glycoprotein Ⅱb/Ⅲa inhibitors for acute coronary syndromes: a cost-effectiveness analysis[J]. J Am Coll Cardiol, 2006,47(3):529-537.
     [15]樊清清,吴玥,段石顽,等.依替巴肽与替罗非班在急性非ST段抬高型心肌梗死患者介入治疗中的药物经济学研究[J].中国医院药学杂志,2021,41(5):516-520.
     [16]潘军. 依替巴肽与替罗非班在急性非ST段抬高型心梗患者介入治疗中的有效性及安全性的对比研究[D]. 河北医科大学, 2015.
     [17]刘国恩,胡善联,吴久鸿,等.中国药物经济学评价指南(2020版)[M]. 北京：中国市场出版社,2020.
     [18]胡盛寿,高润霖,刘力生,等. 《中国心血管病报告2018》概要[J]. 中国循环杂志,2019,34（3）:209-220.
     [19]Kleiman NS, Lincoff AM, Flaker GC, et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators[J]. Circulation, 2000,101(7):751-757.
     [20]韩宝峰,朱志军,沈素,等.肝移植受者免疫抑制药应用的药物经济学研究系统评价[J].药物流行病学杂志,2021,30(4):260-265.

快速检索引用检索图表检索高级检索